A prophylactic subcutaneous dose of the anticoagulant tinzaparin does not influence qPCR-based assessment of circulating levels of miRNA in humans

• Published in: PloS one Vol. 17; no. 11; p. e0277008
• Main Authors: Nilsson, Abraham, Nerhall, Anna Maria, Vechetti, Ivan, Fornander, Lotta, Wiklund, Simon, Alkner, Björn, Schilcher, Jörg, von Walden, Ferdinand
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 03.11.2022; Public Library of Science (PLoS)
• Subjects: Anticoagulants; Biomarkers; Chemical synthesis; Complementary DNA; Deoxyribonucleic acid; Disease; DNA; DNA synthesis; Drug interactions; Health aspects; Heparin; Kruskal-Wallis test; Measurement; Medical research; Medicine, Experimental; MicroRNA; miRNA; Patients; Peptides; Plasma; Plasma levels; Polymerase chain reaction; Ribonucleic acid; RNA; Target detection; Transcription; Variance analysis; Sweden; Germany
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0277008

Circulating microRNAs (miRNAs) have become increasingly popular biomarker candidates in various diseases. However, heparin-based anticoagulants might affect the detection of target miRNAs in blood samples during quantitative polymerase chain reaction (qPCR)-based analysis of miRNAs involving RNA extraction, cDNA synthesis and the polymerase catalyzed reaction. Because low-molecular-weight heparins (LMWH) are widely used in routine healthcare, we aimed to investigate whether a prophylactic dose of the LMWH tinzaparin influences qPCR-based quantification of circulating miRNAs. A total of 30 subjects were included: 16 fracture patients with tinzaparin treatment and 14 non-fracture controls without anticoagulation therapy. To control for the effect of tinzaparin on miRNA analysis an identical concentration of synthetic miRNAs was added to plasma, isolated RNA and prepared complementary DNA (cDNA) from all samples in both groups. No significant difference was observed for cDNA synthesis or qPCR when comparing tinzaparin-treated patients with untreated controls. Among the tinzaparin-treated patients, plasma levels of six endogenous miRNAs (hsa-let-7i-5p, hsa-miR-30e-5p, hsa-miR-222-3p, hsa-miR-1-3p, hsa-miR-133a-3p, hsa-miR-133b) were measured before and one to six hours after a subcutaneous injection of tinzaparin 4500IU. No significant effect was observed for any of the investigated miRNAs. A prophylactic dose of 4500IU tinzaparin does not seem to affect cDNA synthesis or qRT-PCR-based quantification of circulating miRNAs.